论文部分内容阅读
为研究肿瘤标志物 Ｃ Ａ２４２ 免疫放射分析的临床应用价值，应用１２５ Ｉ标记糖类抗原 Ｃ２４２的单克隆抗体 Ｃ Ａ２４２ ，固相珠用单克隆抗体 Ｃ２４１ 包被，建立夹心的免疫放射分析（ Ｉ Ｒ Ｍ Ａ） 。结果表明，１００ 名正常人和５３ 例良性疾病患者，其 Ｃ Ａ２４２ 分别为５６７ ±５８１ Ｕ／ ｍ Ｌ 和６８０ ±４１３ Ｕ／ｍ Ｌ。如果以１７ Ｕ／ｍ Ｌ 为阳性界值测定１６７ 例恶性肿瘤患者，其阳性率为６８３ ％ ；其中胰腺癌、结－ 直肠癌、胃癌和肺癌分别有８００ ％ 、５９７ ％ 、７００ ％ 和６００ ％ 的阳性率，而正常人的假阳性率为４０ ％ 。还对 Ｃ Ａ２４２ 的两种测定方法（ Ｉ Ｒ Ｍ Ａ 和 Ｅ Ｉ Ａ） 做了相关性研究，相关系数（ ｒ） 为０９６ 。同时还应用 Ｒ Ｏ Ｃ 曲线论证了 Ｃ Ａ２４２ 的临床应用和价值。结论是： Ｃ Ａ２４２ 在恶性肿瘤诊断方面有较高的灵敏度和特异性，是一种理想的肿瘤标志物。
In order to study the clinical value of the immunoradiometric analysis of tumor marker C A242, monoclonal antibody C A242 of 125 I-labeled carbohydrate antigen C242 was used, solid beads were coated with monoclonal antibody C241, and a sandwich immunoradiometric assay was established (I R M A). The results showed that the C A242 of 100 normal subjects and 53 patients with benign disease were 5 67 ± 5 81 U/m L and 6 80 ± 4 13 U/m L, respectively. If 17 U/m L is a positive cutoff value, 167 cases of malignant tumors have a positive rate of 68. 3%; among them, pancreatic cancer, colorectal cancer, gastric cancer, and lung cancer have 80%, 59.7%, respectively. The positive rate was 70.0% and 60.0%, while the normal positive rate was 4.0%. A correlation study was also performed on the two measurements of C A242 (I R M A and E I A) with a correlation coefficient (r) of 096. The R O C curve was also used to demonstrate the clinical application and value of C A242. The conclusion is: C A242 has higher sensitivity and specificity in the diagnosis of malignant tumors and is an ideal tumor marker.